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Background: Our previous study showed that SLC22A18 downregulation and promoter methylation were
associated with the development and progression of glioma and the elevated expression of SLC22A18 was found
to increase the sensitivity of glioma U251 cells to the anticancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). In
this study, we investigated the predictive value of SLC22A18 promoter methylation and protein expression in
glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ) therapy.
Patients and methods: SLC22A18 promoter methylation and protein expression were examined by methylation-
specific polymerase chain reaction (MSP) and Western blotting respectively, then we compared SLC22A18 promoter
methylation and protein expression in tumor cell explants in regard to prediction of TMZ response and survival
time of 86 GBM patients.
Results: SLC22A18 promoter methylation was detected in 61 of 86 (71%) samples, whereas 36 of 86 (42%) cases
were scored positive for SLC22A18 protein expression. Overall SLC22A18 promoter methylation was significantly
related to SLC22A18 protein expression, but a subgroup of cases did not follow this association. Multivariate Cox
regression analysis indicated that SLC22A18 protein expression, but not promoter methylation, was significantly
correlated with TMZ therapy. SLC22A18 protein expression predicted a significantly shorter overall survival in 51
patients receiving TMZ therapy, whereas no differences in overall survival were observed in 35 patients without
TMZ therapy.
Conclusions: These results show that lack of SLC22A18 protein expression is superior to promoter methylation as a
predictive tumor biomarker in GBM patients receiving temozolomide therapy.Background
Glioblastoma multiforme (GBM) is the most common
and lethal glial tumor of the adult brain, accounting for
about fifty percent of all gliomas. It is characterized by an
aggressive growth pattern, a marked degree of the inva-
siveness and very poor prognosis. The standard treatment
for malignant glioma patients was resection followed by
radiotherapy in the past many years. Lately a great lot of
researches revealed a statistically significant survival bene-
fit for GBM patients treated with radiotherapy plus
temozolomide (TMZ) [1,2]. Consequently, radiotherapy* Correspondence: shenghuachu@126.com
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reproduction in any medium, provided the orplus concurrent TMZ therapy currently represents the
standard of care for newly diagnosed GBM patients [3].
Solute carrier family 22 (organic cation transporter)
member 18 (SLC22A18), also known as IMPT1/BWR1A/
TSSC5, is located within the human 11p15.5 cluster [4,5].
Blast homology analysis suggests that SLC22A18 is a
member of the family of polyspecific transporters and
multidrug resistance genes [5]. More recently, SLC22A18
has been shown to be a tumor suppressor candidate and a
substrate for RING105 [6]. Structural mutations in
SLC22A18 are rare, with isolated reports of point muta-
tions in a breast cancer cell line [7], a rhabdomyosarcoma
cell line [5], and Wilms’ tumors and lung tumors [8]. Ex-
onic deletions in Wilms’ tumors and loss of heterozygosity
in hepatoblastomas have also been reported [9], indicating
that SLC22A18 may play a role in tumorigenesis. We have. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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moter methylation were associated with the development
and progression of glioma and SLC22A18 represented a
candidate biomarker for long-term survival in this disease,
suggesting that SLC22A18 is an important tumor suppres-
sor in glioma [10,11]. We have also found that the ele-
vated expression of SLC22A18 was found to increase the
sensitivity of glioma U251 cells to the anticancer drug 1,3-
bis(2-chloroethyl)-1-nitrosourea (BCNU) [12].
In this study, for the first time we used primary tumor
cell explants obtained from GBM surgical specimens in-
stead of tissue samples to investigate SLC22A18 methy-
lation promoter and protein expression of tumor cell.
Our data presented show that expression of SLC22A18
protein has a very strong predictive value for TMZ re-
sponse and survival time in GBM patients.
Materials and methods
Study patients
We collected 86 cases of surgically resected GBMs in
the period ranging from 2007–2010 at the Department
of Neurosurgery, NO.3 People's Hospital Affiliated to
Shanghai Jiao Tong University School of Medicine and
Zhongnan Hospital of Wuhan University. Informed pa-
tient consent and prior approval from the NO.3 People’s
Hospital Affiliated to Shanghai Jiao Tong University School
of Medicine and Zhongnan Hospital of Wuhan UniversityTable 1 Characteristics of the patients according to SLC22A18









Male 46(53) 36(59) 10(40)
Fmale 40(47) 25(41) 15(60)
Age (years)
<45 13(15) 8(13) 5(20)
≥45 73(85) 53(87) 20(80)
Performance status
<90 39(45) 27(44) 12(48)
≥90 47(55) 34(56) 13(52)
Extent of surgery
Total 45(52) 34(56) 11(44)
Not total 41(48) 27(44) 14(56)
MGMT promoter
Unmethylation 29(34) 18(30) 11(44)
Methylation 57(66) 43(70) 14(56)
TMZ therapy
Yes 50(58) 37(61) 13(52)
No 36(42) 24(39) 12(48)Ethics Committees (Ethic approval ZNHWHU0389,NTPH-
SHJTUSM046) was obtained before the clinical materials
were used for research purposes. All experiments on
humans in the present study were performed in compliance
with the Helsinki Declaration. Gadolinium-enhanced MRI
performed within 1 week after surgery was used to cate-
gorize the surgical results according to the removed tumor
proportion, i.e., biopsy, ≤ 50%; partial removal, 50-95%; sub-
total removal, 96-99%; total removal, >99%. There were 46
men and 40 women with a mean age of 62.5 years (range
from 14 to 78 years). None of the patients had received
chemical therapy or radiotherapy prior to surgery. 50 pa-
tients received concurrent radiotherapy and chemotherapy
(60 Gy and daily TMZ at 75 mg/m2; 7 days per week over a
42-day period) after surgery. 30 patients received the adju-
vant TMZ after concurrent radio-temozolomide therapy.
36 patients did not receive chemotherapy, out of which 18
had only radiotherapy and 18 did not have further therapy.
Characteristics of the patients according to SLC22A18 pro-
moter methylation and protein expression status were
shown in Table 1.
Primary tumor cell cultures
After removing visible blood vessel and necrotic tissues,
surgery specimens were processed for primary cell cultures
as described previously [13-15], and analyzed between pas-













0.11 21(58) 25(50) 0.45
15(42) 25(50)
0.42 4(11) 9(18) 0.38
32(89) 41(82)
0.75 16(44) 23(46) 0.89
20(56) 27(54)
0.32 19(67) 26(42) 0.94
17(33) 24(58)
0.20 12(33) 17(34) 0.95
24(67) 33(66)
0.46 23(64) 27(54) 0.36
13(36) 23(46)
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and transferred into culture flasks, containing growth
medium (RPMI-1640, 20% fetal bovine serum, 1% penicil-
lin/streptomycine, 1% glutamine; Gibco Life Technologies,
Paisley, Scotland, UK). Three to five culture flasks were set
up from each surgery specimen. Cells were then cultured
in RPMI-1640 supplemented with 10% fetal bovine serum
and 1% glutamine and without antibiotics. The presence of
predominantly malignant cells in primary cell cultures was
proved by comparative genomic hybridization and/or
fluorescent in situ hybridization analyses [13]. All cell cul-
tures were periodically checked for Mycoplasma contamin-
ation using a Mycoplasma Stain Kit (Sigma-Aldrich, St.
Louis, Missouri, USA) [16].
DNA extraction and methylation-specific polymerase
chain reaction
As we’ve previously described [10,17], genomic DNA was
extracted from tumor cell cultures or frozen surgery tissues
by the digestion with proteinase K (Fisher Scientific,
Fairlawn, NJ, USA) using a genomic DNA purification kit
(PureGene kit, Gentra Systems, Inc., Minneapolis, MN,
USA), and 1 μg genomic DNA was treated with a CpG
WIZ DNA Modification Kit (EMD Millipore Corporation,
Billerica, MA, USA) to convert unmethylated cytosines to
uracil, leaving methylated cytosines unchanged. The modi-
fied DNA was diluted in TE buffer (10 mM Tris-Cl, pH 7.5.
1 mM EDTA). SLC22A18 and MGMT promoter methyla-
tion analysis was performed by PCR, using bisulfite-treated
DNA as template, with specific primers for the methyla-
ted (unmodified by bisulfite treatment) and unmethylated
(bisulfite modified) gene sequences using the methylation-
specific polymerase chain reaction (MSP) method [10,17].
Expression levels were quantified by Quantity One Quanti-
tation software (BioRad) and calculated relative to the con-
trols. The results were confirmed by repeating the bisulfite
treatment and MSP assays for all samples.
Western blot analysis
As we’ve previously described [18-20], tumor cell cultures
were washed in ice-cold PBS and lysed in buffer using
standard methods. tumor tissues were homogenized in a
RIPA lysis buffer. Lysates were cleared by centrifugation
(14, 000 rpm) at 4°C for 30 minutes. Protein samples
(approximately 40 μg) were separated by SDS-PAGE
(15% gel), transferred to PVDF membrane and non-
specific binding sites blocked by incubation in 5% non-fat
milk for 60 minutes. Membranes were incubated over-
night at 4°C with polyclonal anti-SLC22A18 antibody
(1:1,000 dilution; Santa Cruz, CA). The membrane was
then washed three times with TBST for 10 minutes and
probed with HRP-conjugated secondary antibody (at
1:2,000 dilution; Dako, Glostrap, Denmark) for 30 minutes
at room temperature. Visualization and quantificationwere done using the ChemiDoc System (BioRad). Data
gained by the densitometric analysis of Western blotting
for SLC22A18 were expressed relative (arbitrary units) to
the SLC22A18 expressing human neurons (ScienCell Re-
search Laboratories, San Diego, CA, USA) that is included
as a positive control in each blot and set arbitrarily as 1.
Each assay was performed in triplicate.
Statistical analyses
Statistical analyses and graphs were performed using the
Statistical Package for the Social Sciences (version 16.0, for
Windows) (SPSS, Chicago, IL, USA). Quantitative values
were expressed as mean ± SD. Statistical differences be-
tween groups were examined using the Fisher’s exact test.
P-values less than 0.05 were considered statistically
significant.
Results
SLC22A18 promoter methylation and protein expression
Primary tumor cell culture was successful in vitro in all sur-
gery specimens, allowing SLC22A18 promoter methylation
and protein expression analyses. In 61 of 86 (71%) GBM
cases methylated SLC22A18 gene promoter sequences were
detected. Out of the 61 samples with methylated sequences,
24 samples contained a mixed profile with varying propor-
tions of unmethylated and methylated sequences, whereas
the remaining 37 cases (61%) lacked any unmethylated
DNA (Figure 1A-B). SLC22A18 promoter was completely
unmethylated in 25 of 86 (29%) GBM cases. To investigate
the potential influence of tumor cell culture, SLC22A18
promoter methylation was determined in both surgical tis-
sues and the respective tumor cell cultures in 86 cases.
SLC22A18 methylation status agreed well in all patients
(see Additional file 1: Table S1), and semi-quantification of
MSP products for methylated DNA sequences showed a
significant correlation (linear regression analysis, P < 0.001).
In all cell cultures SLC22A18 protein expressions were suc-
cessfully analyzed by Western blotting (Figure 1C). 36 of
the 86 cases (42%) were scored positive for SLC22A18 pro-
tein expression based on a visible band and corresponding
to a relative expression level > 0.1. Neither SLC22A18 pro-
moter methylation nor protein expression was significantly
correlated with any of the clinical features listed in Table 1.
The mean SLC22A18 expression levels were signifi-
cantly lower in tumor cell cultures harboring methylated
SLC22A18 promoter sequences when compared with only
unmethylated subgroup (P < 0.001) (Figure 1D). Therefore,
SLC22A18 protein expression was significantly associated
with promoter methylation status when analyzed by 2-sided
χ2 test (P < 0.001). SLC22A18 protein expression levels in
the subgroups were strongly overlapping according to pro-
moter methylation despite this association (Figure 1D). In
Figure 2 data of 4 representative samples that did not follow
the correlation between SLC22A18 protein expression and
Figure 1 Analysis of SLC22A18 promoter methylation and protein expression in GBM cell cultures explanted from surgical specimens.
(A) CpG island of SLC22A18 gene with location and sequence of methylation-specific polymerase chain reaction (MSP) primers (uf, forward
U-MSP primer; ur, reverse U-MSP primer; mf, forward M-MSP primer; mr, reverse M-MSP primer). (B) Representative images of MSP analysis of
SLC22A18 promoter methylation. Amplification products with specific primers for unmethylated (u) and methylated (m) DNA sequences are
indicated, and scoring as unmethylated (u), methylated (m), and mixed (u/m) is shown. Positive controls for unmethylated (pcu) and methylated
(pcm) sequences were included. M, size marker. (C) Representative images of western blotting analysis of SLC22A18 protein expression, and levels
of relative expression were gained by the densitometric analysis of Western blotting compared with the SLC22A18 expressing human neurons
included as positive control (pc) and set arbitrarily as 1. β-actin was used as loading control. (D) Scatter gram analysis of SLC22A18 protein
expression in two subgroups with methylated and unmethylated SLC22A18 promoter sequences.
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included cases with exclusively unmethylated promoter se-
quences but lack of SLC22A18 protein expression as well
as high expression of SLC22A18 protein, despite completely
methylated promoter.Relationship between SLC22A18 status and overall
survival of GBM patients with/without TMZ therapy
58 (67%) of 86 cases had died (34 of 35 cases without
TMZ treatment and 24 of 51 cases with TMZ treatment)
at a median follow-up time of 27.1 months (95% CI
Figure 2 Discrepancy between SLC22A18 promoter methylation and protein expression. Representative samples for SLC22A18 promoter
methylation and protein expression (1, 2) as well as lack of promoter methylation and protein expression (3, 4) are shown. (A) Polyacrylamide gel
showing amplification products of unmethylated and methylated DNA sequences by MSP. Positive controls for unmethylated (pcu) and
methylated (pcm) sequences were shown. (B) Western blot analysis for the corresponding cases.
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GBM patients was compared to SLC22A18 protein ex-
pression or promoter methylation status (Table 2). In
the univariate analysis lack of SLC22A18 protein expres-
sion (hazard ratio [HR] of death 2.14, 95% CI 1.24-3.72;
P = 0.01), but not promoter methylation status (HR of
death 0.64, 95% CI 0.32-1.15; P = 0.13), was significantly
connected with shorter overall survival in addition to
well-known prognostic factors such as age, performance
status, extent of surgery, MGMT promoter methylation
and TMZ therapy. Besides age, performance status, ex-
tent of surgery, MGMT promoter methylation and TMZ
therapy, only lack of SLC22A18 protein expression, but
not SLC22A18 promoter methylation status, remained
as an independent prognostic factor (HR of death 2.11,
95% CI 1.09-3.77; P = 0.02) in multivariate Cox regres-
sion analysis (Table 3). An interaction term, the product
of SLC22A18 parameter and TMZ therapy, was incorpo-
rated into the multivariate Cox regression models to
evaluate a possible interaction between the SLC22A18 pa-
rameters and TMZ treatment. These findings showed a
statistically significant association between SLC22A18 pro-
tein expression and TMZ treatment (P = 0.004), whereas in
the case of SLC22A18 promoter methylation this inter-
action was not significant. Because the interaction term of
SLC22A18 protein expression and TMZ therapy wasTable 2 Univariate survival analysis
Variable HR 95% CI P value
Gender 0.75 0.38-1.32 0.24
Age 1.12 1.02-1.14 < 0.001
Performance status 0.98 0.92-1.02 < 0.001
Extent of surgery 0.14 0.10-0.28 < 0.001
MGMT methylation 1.25 1.12-1.32 0.006
TMZ therapy 0.24 0.12-0.41 < 0.001
SLC22A18 promoter methylation 0.64 0.32-1.15 0.13
SLC22A18 protein expression 2.14 1.24-3.72 0.01significant, we studied the relationship between SLC22A18
protein expression and overall survival time in TMZ ther-
apy and no TMZ therapy subgroups (Table 4, Figure 3A
and B). In patients with TMZ therapy, SLC22A18 protein
expression was significantly associated with longer overall
survival time (HR of death 5.65, 95% CI 1.79-17.45; P =
0.002). Conversely, no differences in overall survival time
according to SLC22A18 protein expression (HR of death
1.12, 95% CI 0.56-2.28; P = 0.62) were shown in patients
without TMZ therapy. A similar study using the subgroups
according to promoter methylation status showed no sig-
nificant differences with overall survival time in the TMZ
therapy subgroup (Figure 3C and D).Discussion
We have previously found that SLC22A18 protein expres-
sion was significantly decreased in human gliomas com-
pared to the adjacent normal brain tissues. SLC22A18
protein expression was significantly lower in gliomas which
recurred within six months after surgery than gliomas
which did not recur within six months. Multivariate Cox
regression analysis indicated that SLC22A18 expression
level was an independent survival prognostic factor for pa-
tients with glioma. SLC22A18 promoter methylation was
detected in 50% of the gliomas, but not in the adjacent nor-
mal tissues of any patient. SLC22A18 expression was sig-
nificantly decreased in gliomas with SLC22A18 promoter
methylation, compared to gliomas without methylation.
The SLC22A18 promoter was methylated in U251 cells
and treatment with the demethylating agent 5-aza-
2-deoxycytidine increased SLC22A18 expression and re-
duced cell proliferation. Stable overexpression of SLC22A18
inhibited growth and adherence, induced apoptosis in vitro
and reduced in vivo tumor growth of U251 cells [10,11,21].
We have also found that elevated expression of SLC22A18
increased the sensitivity of U251 glioma cells to BCNU
[12]. Recently we have found that by increasing the expres-
sion of SLC22A18 hydroxyapatite nanoparticles could
Table 3 Multivariate survival analysis
Promoter methylation Protein expression
HR 95% CI P value HR 95% CI P value
Variable without interaction term
Gender 0.83 0.41-1.52 0.44 0.95 0.46-1.76 0.86
Age 1.10 1.01-1.20 0.002 1.10 1.01-1.12 0.002
Performance status 0.98 0.92-1.02 0.001 0.98 0.92-1.02 0.001
Extent of surgery 0.14 0.08-0.22 < 0.001 0.14 0.08-0.24 < 0.001
MGMT promoter 1.32 1.11-1.56 0.012 1.32 1.11-1.55 0.012
TMZ therapy 0.29 0.14-0.50 < 0.001 0.29 0.14-0.49 < 0.001
Promoter methylation 0.62 0.31-1.19 0.15
Protein expression 2.11 1.09-3.77 0.02
Variable with interaction terms
Gender 0.83 0.41-1.55 0.46 1.02 0.50-1.87 0.95
Age 1.10 1.01-1.20 0.002 1.10 1.01-1.22 0.001
Performance status 0.98 0.92-1.03 0.002 0.98 0.92-1.02 0.001
Extent of surgery 0.14 0.08-0.22 < 0.001 0.14 0.08-0.34 < 0.001
MGMT promoter 1.32 1.11-1.57 0.018 1.32 1.11-1.55 0.012
TMZ therapy 0.32 0.11-0.83 0.02 0.11 0.03-0.25 < 0.001
Promoter methylation 0.67 0.59-2.91 0.33
Protein expression 1.06 0.45-2.11 0.45
Promoter methylation × TMZ therapy 0.83
Protein expression × TMZ therapy 0.004
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in vivo [18].
In the present study, we have studied the relationship be-
tween SLC22A18 promoter methylation and protein ex-
pression and the association of these two parameters with
TMZ treatment as well as overall survival time of GBM pa-
tients. We determined SLC22A18 protein expression by
Western blot analysis in primary tumor cells derived from
the surgical specimens instead of tissue sections or tumor
extracts in order to focus completely on the malignant cell
compartment. To avoid problems arising from the tissue
fixation and paraffin embedding, we used cell cultures-
derived DNA for detection of SLC22A18 promoter methy-





Performance status 0.97 0.90-1.02
Extent of surgery 1.05 0.98-1.12
MGMT promoter 5.85 1.86-18.02
SLC22A18 Protein expression 5.65 1.79-17.45tumor cells and snap-frozen tissue in a subgroup of tumors,
confirming the presence of methylated SLC22A18 pro-
moter sequences in all cases. During short-term in vitro
cultivation of tumor cells, the observations also exclude
possible changes in the SLC22A18 promoter methylation
status. Using this new method, we demonstrate that
SLC22A18 protein expression is a strong important predict-
ive marker for the response of TMZ therapy and the related
survival benefit. our results showed SLC22A18 protein ex-
pression was associated with longer overall survival time.
Especially in patients with TMZ therapy, SLC22A18 protein
expression was significantly associated with longer overall
survival time, and in patients without TMZ therapy no sig-
nificant differences in overall survival time according toegarding TMZ therapy
No TMZ therapy
P value HR 95% CI P value
0.08 1.82 0.76-4.06 0.12
0.005 1.10 0.98-1.14 0.03
0.006 0.99 0.92-1.04 0.01
0.003 1.02 0.96-1.18 0.01
0.001 1.25 0.62-2.34 0.74
0.002 1.12 0.56-2.28 0.62
Figure 3 SLC22A18 promoter methylation status and protein expression when compared with overall survival time of cases. Results of
Kaplan-Meier analyses of overall survival time according to SLC22A18 protein expression (A and B) or promoter methylation (C and D) of GBM
patients with TMZ therapy (A and C) and without TMZ therapy (B and D) are shown.
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the discrepancy of SLC22A18 expression in different tumor
patients and a patient subgroup are unclear so far. Thus, fu-
ture studies with larger sample sizes should be done to con-
firm this trend. SLC22A18 protein expression was of
superior predictive value in GBM patients in our study des-
pite a strong association between SLC22A18 promoter
methylation and protein expression. These findings show
that reliable SLC22A18 protein detection approach has to
be developed to identify GBM patients likely to benefit
from TMZ treatment. Consistent with this idea [10], the
SLC22A18 parameters showed significant correlation in this
study, confirming that SLC22A18 promoter methylation is
a major factor regulating SLC22A18 protein expression.
However, as obvious from the scatter grams (Figure 1D)
and depicted by selected patients (Figure 2), there are some
tumor cell samples not following this association. This
shows that SLC22A18 protein is still expressed in a sub-
group of tumors with SLC22A18 promoter methylation
and vice versa. The reasons for the discrepancy between
SLC22A18 expression and promoter methylation in a pa-
tient subgroup are unclear so far. Our results show that epi-
genetic silencing via promoter methylation is an important
but obviously not always decisive factor regulatingSLC22A18 expression in GBM cells. With respect to ther-
apy response and overall survival, SLC22A18 protein ex-
pression proved to be of significantly higher predictive
power when compared with promoter methylation status in
our samples. Our attempts to analyze SLC22A18 expres-
sion by immunohistochemistry in selected patient samples
used in this study were inconclusive, and immunostaining
neither correlated with SLC22A18 expression nor promoter
methylation detected by Western blot, even when using
identical antibodies (data not shown). Our data based on
tumor cell explants and Western blot analysis turn out the
high quality of SLC22A18 expression as a predictive marker
for TMZ response in patients with GBM.
Conclusions
Collectively, we analyzed the influence of SLC22A18 status
on the response of TMZ treatment and survival time of
GBM patients by using a completely novel approach. Evalu-
ation of SLC22A18 protein levels in GBM cell cultures de-
rived from surgical specimens was proved to be a strongly
predictive indicator for TMZ therapy-mediated survival
time benefit with superior information power as compared
to the MSP analysis of SLC22A18 promoter methylation.
Accordingly, reproducible and reliable SLC22A18 protein
Chu et al. Journal of Translational Medicine 2013, 11:69 Page 8 of 8
http://www.translational-medicine.com/content/11/1/69detection methods have to be developed and tested with re-
spect to their predictive value for the response of TMZ
treatment in prospective studies involving more GBM
patients.
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